Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 482-490

  Marnett, Lawrence J ^a   Kalgutkar, Amit S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANIMAL; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG DESIGN; GASTROINTESTINAL DISEASE; HUMAN; METABOLISM; REVIEW; ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; GASTROINTESTINAL DISEASES; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MODELS, MOLECULAR; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; ULCER;

EID: 0032135008     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80124-5     Document Type: Article

References (61)

1. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:33157-33160.
2. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta Lipids - Lipid Metab 1996, 1299:125-140.
3. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL: Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994, 271:927-934.
4. Xie W, Robertson DL, Simmons DL: Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992, 25:249-265.
5. DeWitt DL, Meade EA, Smith WL: PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993, 95:2A40S-2A44S.
6. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994, 91:3228-3232.
7. 2 synthase-1. Nature 1994, 367:243-249.
8. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF: Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996, 3:927-933.
9. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K et al.: Structural basis for selective inhibition of cyclooxygenase- 2 by anti-inflammatory agents. Nature 1996, 384:644-648.
10. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR: Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992, 267:4338-4344.
11. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88:2692-2696.
12. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992, 89:7384-7388.
13. Rome LH, Lands WEM: Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975, 72:4863-4865.
14. Copeland RA, Williams JM, Giannaras J, Numberg S, Covington M, Pinto D, Pick S, Trzaskos JM: Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994, 91:11202-11206.
15. Loll PJ, Picot D, Garavito RM: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995, 2:637-642.
16. 2 synthase cyclooxygenase active site. Biochemistry 1996, 35:7330-7340.
17. Bhattacharyya DK, Lecomte M, Rieke CJ, Garavito RM, Smith WL; Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem 1996, 271:2179-2184.
18. Mancini JA, Riendeau D, Falgueyret J-P, Vickers PJ, O'Neill GP: Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem 1995, 270:29372-29377.
19. Karthein R, Dietz R, Nastainczyk W, Ruf HH: Higher oxidation states of prostaglandin H synthase. EPR study of a transient tyrosyl radical in the enzyme during the peroxidase reaction. Eur J Biochem 1988, 171:313-320.
20. DeGray JA, Lassmann G, Curtis JF, Kennedy TA, Marnett LJ, Eling TE, Mason RP: Spectral analysis of the protein-derived tyrosyl radicals from prostaglandin H synthase. J Biol Chem 1992, 267:23583-23588.
21. Tsai A-L, Palmer G, Xiao G, Swinney DC, Kulmacz RJ: Structural characterization of arachidonyl radicals formed by prostaglandin H synthase-2 and prostaglandin H synthase-1 reconstituted with mangano protoporphyrin IX. J Biol Chem 1998, 273:3888-3894.
22. Goodwin DC, Gunther MH, Hsi LH, Crews BC, Eling TE, Mason RP, Marnett LJ: Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover: Detection of the radical derivative of tyrosine 385. J Biol Chem 1998, 273:8903-8909.
23. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR: Antiinflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990, 254:180-187.
24. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47:55-59.
25. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay R, Hill RG, Li C-S, Mancini J, Penneton M et al.: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995, 274:1531-1537.
26. Nakamura K, Tsuji K, Konishi N, Okumura H, Matsuo M: Studies on antiiflammatory agents. II. Synthesis and pharmacological properties of 2′-(phenylthio)methanesuflonamides and related derivatives. Chem Pharm Bull (Tokyo) 1993, 41:894-906.
27. Prasit P, Riendeau D: Selective cyclooxygenase-2 inhibitors. In Annual Reports in Medicinal Chemistry, vol 32. Edited by Hagmann WK. New York: Academic Press Inc; 1997:211-220. A comprehensive review on the development of selective cyclooxygenase-2 (COX-2) inhibitors with particular emphasis on structure/activity relationship studies and relevant pharmacological data on lead compounds. The article also reveals the chemical structures with the corresponding inhibition profile of novel and selective COX-2 inhibitors, which have not been published before.
28. Gauthier JY, Leblanc Y, Black WC, Chan C-C, Cromlish WA, Gordon R, Kennedy RP, Lau CK, Léger S, Wang Z et al.: Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 inhibitors. Part II: replacing the heterocycle. Bioorg Med Chem Letts 1996, 6:87-92.
29. Roy P, Lelbanc Y, Ball RG, Brideau C, Chan CC, Chauret N, Cromlish W, Ethier D, Gauthier JY, Gordon R et al.: A new series of selective COX-2 inhibitors: 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles. Bioorg Med Chem Letts 1997, 7:57-62.
30. Thérien M, Brideau C, Chan CC, Cromlish WA, Gauthier JY, Gordon R, Greiog G, Kargman S, Lau CK, Leblanc Y et al.: Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors. Bioorg Med Chem Letts 1997, 7:47-52. The sulfur atom contained on the thiazole ring of the lead compound in the diarylimidazolothiazole series (see [29]) undergoes oxidation in the presence of liver microsomes to the toxic thiazolo-S-oxide (analogous to the toxicity associated with vinyl sulfoxides). This paper describes an elegant structural modification of the toxic imidazolothiazoles to the nontoxic thiazolotriazoles; oxidative metabolism of the sulfur is prevented due to steric hindrance provided by the pendant phenyl rings around the sulfur.
31. Li JJ, Norton MB, Reinhard EJ, Anderson GD, Gregory SA, Isakson PC, Koboldt CM, Masferrer JL, Perkins WE, Seibert K et al.: Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J Med Chem 1996, 39:1846-1856.
32. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Doctor S, Graneto MJ, Lee IF, Malecha JW, Miyashiro JM et al.: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 1997, 40:1347-1365. Structure/activity relationship studies on Searle's early lead compound SC-58125, leading to the development of SC-58635 (Celecoxib), are reported. One of the major structural differences between Celecoxib and SC-58125 is that the former contains a sulfonamide moiety, whereas a methylsulfonyl substituent is present in SC-58125. The presence of the sulfonamide moiety in Celecoxib results in a lower cyclooxygenase selectivity ratio than SC-58125; however, it was elected for clinical trials based on its overall in vivo efficacy. Celecoxib is currently in phase III clinical trials for the treatment of osteoarthritis.
33. Tsuji K, Nakamura K, Konishi N, Tojo T, Ochi T, Senoh H, Matsuo M: Studies on antiinflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem Pharm Bull 1997, 45:987-995.
34. Friesen RW, Dube D, Fortin R, Frenette R, Prescott S, Cromlish W, Greig GM, Kargman S, Wong E, Chan CC, Gordon R et al.: Novel 1,2-diarylbutenes: selective and orally active COX-2 inhibitors. Bioorg Med Chem Letts 1996, 6:2677-2682.
35. 50 values of the furanone with several selective and nonselective inhibitors is also included. The results are consistent with the finding by Copeland et al. [14] that COX-2-selective inhibitors derive their selectivity on the basis of their slow, time-dependent inhibition, as they retain their ability to reversibly inhibit both isoforms.
36. Huang HC, Li JJ, Garland DJ, Chamberlain TS, Reinhard EJ, Manning RE, Seibert K, Koboldt CM, Gregory SA, Anderson GD, Veenhuizen AW et al.: Diarylspiro[2.4]heptenes as orally active highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships. J Med Chem 1996, 39:253-266.
37. Khanna IK, Weier RM, Yu Y, Xu XD, Koszyk FJ, Collins PW, Koboldt CM, Veenhuizen AW, Perkins WE, Casier JJ et al.: 1,2-Diarylimidazoles as potent cyclooxygenase-2 selective, and orally active antiinflammatory agents. J Med Chem 1997, 40:1634-1647.
38. Khanna IK, Weier RM, Yu Y, Collins PW, Miyashiro JM, Koboldt CM, Veenhuizen AW, Curie JL, Seibert K, Isakson PC: 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem 1997, 40:1619-1633.
39. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K: A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996, 271:15810-15814.
40. 523→Val mutation. J Biol Chem 1997, 272:9280-9286. This study expands on the results of Gierse et al. [39]. In addition to Ile523, His513 in cyclooxygenase-1 (COX-1) is not conserved between the two isozymes and is replaced by an arginine residue in COX-2. The residues Ile523 and His513 in COX-1 were individually mutated to valine and arginine, respectively, and a double mutant (His513→Arg/Ile523 Val) was constructed. These mutants had no effect on catalysis but were sensitive to time-dependent inhibition by selective COX-2 inhibitors. This studies complements the finding of Gierse et al. [39] in that mutations were made in COX-1, rendering it sensitive to COX-2 inhibitors.
41. 509 in time-dependent inhibition of prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J Biol Chem 1996, 271:19134-19139.
42. Song Y, Connor DT, Sorenson RJ, Doubleday R, Sercel AD, Unangst PC, Gilbertsen RB, Chan K, Bornemeier DA, Dyer RD: 2,6-Di-tert-butylphenols: a new class of potent and selective PGHS-2 inhibitor, Inflamm Res 1997, 46:S141-S142. The Parke-Davis group has disclosed 2,6-di-tert-butylphenols as a new class of selective cyclooxygenase-2 (COX-2) inhibitors. These compounds are structurally different from the traditional diarylheterocycles or the acidic sulfonamides. The lead compounds display COX-2 selective inhibition against purified human COX-2 and in cellular assays. Incidently, analogous di-tert-butylphenols have also been shown to inhibit 5-lipoxygenase and it is not known whether these particular analogs are capable of inhibiting lipoxygenases.
43. Black WC, Bayly C, Belley M, Chan C-C, Charleson S, Denis D, Gauthier JY, Gordon R, Guay D, Kargman S et al.: From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Letts 1996, 6:725-730.
44. Leblanc Y, Black WC, Chan CC, Charleson S, Delorme D, Denis D, Gauthier JY, Grimm EL, Gordon R, Guay D et al.: Synthesis and biological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2. Bioorg Med Chem Letts 1996, 6:731-736.
45. Lazer ES, Miao CK, Cywin CL, Sorcek R, Wong H-C, Meng Z, Potocki I, Hoermann MA, Snow RJ, Tschantz MA et al.: Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem 1997, 40:980-989. The introduction of meloxicam as a nonsteroidal antiinflammatory drug (NSAID) led to further structure/activity relationship development in the enolcarboxamide class of compounds as selective cyclooxygenase-2 (COX-2) inhibitors. Interestingly, meloxicam was developed as an NSAID prior to the discovery of COX-2. This paper reports that meloxicam has a 75-fold selectivity for COX-2, whereas Ogmo et al. [46] report a 12-fold COX-2 selectivity by meloxicam.
46. Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y: Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 1997, 55:44-53.
47. Engelhardt G, Bogel R, Schnitzler Chr, Utzmann R: Meloxicam: influence on arachidonic acid metabolism Part I. In vitro findings. Biochem Pharmacol 1996, 51:21-28.
48. Engelhardt G, Bogel R, Schnitzler Chr, Ultzmann R: Meloxicam: influence on arachidonic acid metabolism part II. In vivo findings. Biochem Pharmacol 1996, 51:29-38.
49. Roth GJ,Stanford N, Majerus PW: Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975, 72:3073-3076.
50. Kurumbail R, Pawlitz JL, Stevens AM, Stageman RA, Cierse JK, Kobolt CM, Seibert K, Isakson PC, Stallings WC: Structural basis for time-dependent inhibition of cyclooxygenases. In Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases. Edited by Honn KV, Nigam S, Marnett LJ, Dennis E. New York: Plenum Publishing Corp; 1998: in press.
51. Kulmacz RJ, Wu KK: Topographic studies of microsomal and pure prostaglandin H synthase. Arch Biochem Biophys 1989, 268:502-515.
52. Kalgutkar AS, Crews BC, Marnett LJ: Kinetics of the interaction of nonsteroidal antiinflammatory drugs with prostaglandin endoperoxide synthase-1 studied by limited proteolysis. Biochemistry 1996, 35:9076-9082.
53. Kulmacz RJ, Lands WEM: Protection of prostaglandin H synthase from trypsin upon binding of heme. Biochem Biophys Res Comm 1982, 104:758-764.
54. Chen Y-NP, Bienkowski MJ, Marnett LJ: Controlled tryptic digestion of prostaglandin H synthase. J Biol Chem 1987, 252:16892-16899.
55. Morham SG, Lagenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473-482.
56. Lagenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995, 83:483-492.
57. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM et al.: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406-409.
58. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Ohishi S, Narumiya S: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682.
59. Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, Oida H, Yoshida N, Tanaka T, Katsuyama M et al.: Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997, 277:681-683.
60. Weisenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J: The pharmacological profile of CPG 28238, a novel highly potent anti-inflammatory compound. Drugs Exp Clin Res 1989, 15:501-509.
61. Kalgutkar AS, Crews BC, Rowlinson SW, GArner C, Seibert K, Marnett LJ: Asprin-like molecules that covelently inactivate cyclooxygenase-2. Science 1998, 280:1268-1270.